Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria

Olle Erikssona,*, Anders Wallb, Ina Marteinsdottirc, Hans Ågren d, Per Hartvig e, Gunnar Blomqvist b, Bengt Långström b, Tord Naessén a

aDepartment of Women’s and Children’s Health/Obstetrics and Gynecology, University Hospital, SE-751 85 Uppsala, Sweden
bUppsala Imanet AB, University Hospital, SE-751 85 Uppsala, Sweden
cDepartment of Neuroscience, Section of Psychiatry, University Hospital, SE-751 85 Uppsala, Sweden
dNeurotec Department, Division of Psychiatry, Karolinska Institute, SE-171 76 Stockholm, Sweden
eHospital Pharmacy, University Hospital, SE-751 85 Uppsala, Sweden

Received 27 July 2004; received in revised form 20 December 2004; accepted 14 February 2005

Abstract

The cardinal mood symptoms of premenstrual dysphoria can be effectively treated by serotonin-augmenting drugs. The aim of the study was to test the serotonin hypothesis of this disorder, i.e. of an association between premenstrual decline in brain serotonin function and concomitant worsening of self-rated cardinal mood symptoms. Positron emission tomography was used to assess changes in brain trapping of 11C-labeled 5-hydroxytryptophan, the immediate precursor of serotonin, in the follicular and premenstrual phases of the menstrual cycle in eight women with premenstrual dysphoria. Changes in mood and physical symptoms were assessed from daily visual analog scale ratings. Worsening of cardinal mood symptoms showed significant inverse associations with changes in brain serotonin precursor trapping; for the symptom “irritable”, $r_s = -0.83$, and for “depressed mood” $r_s = -0.81$. Positive mood variables showed positive associations, whereas physical symptoms generally displayed weak or no associations. The data indicate strong inverse associations between worsening of cardinal symptoms of premenstrual dysphoria and brain serotonin precursor ($^{11}$C-labeled 5-hydroxytryptophan) trapping. The results may in part support a role for serotonin in premenstrual dysphoria and may provide a clue to the effectiveness of serotonin-augmenting drugs in this disorder but should, due to small sample size and methodological shortcomings, be considered preliminary.

Keywords: Affective symptoms; 5-Hydroxytryptophan; Positron emission tomography; Premenstrual dysphoric disorder; Premenstrual syndrome; Right caudate nucleus

1. Introduction

Premenstrual dysphoric disorder (PMDD) is characterized by the cyclical occurrence of disabling mood symptoms in the luteal (premenstrual) phase of the menstrual cycle, with a profound impact on the afflicted woman and her near environment (American Psychiatric Association, 1994). The cardinal symptoms are irritability, depressed mood, affective lability and impaired impulse control, all of which are effectively alleviated by drugs increasing brain serotonin activity (Eriksson, 1999). Randomised trials have shown selective serotonin reuptake inhibitors (SSRIs) to be effective pharmacological treatments in about 60% of women with PMDD (Rapkin, 2003), and these drugs are considered the...
most effective treatment known at present (Dimmock et al., 2000). This implies that reduced serotonergic activity might be one symptom-provoking factor in premenstrual dysphoria, supporting the “serotonin hypothesis” of the pathogenesis of the disorder, namely that worsening of self-rated premenstrual mood symptoms is associated with a concomitant decline in brain serotonin activity (Steiner and Pearlstein, 2000; Parry, 2001; Eriksson et al., 2002). Positron emission tomography (PET) was used to measure brain trapping of $^{11}$C-5-hydroxy-L-tryptophan ($^{11}$C-5-HTP), which when radiolabeled in the metabolically stable $\beta$-position is a marker of aromatic L-amino-acid decarboxylase (AAAD) activity (Bjurling et al., 1990; Hartvig et al., 1992, 1993; Lindner et al., 1997). Associations between changes in cardinal symptoms of PMDD and changes in brain $^{11}$C-5-HTP trapping from early (mid-follicular) to late (premenstrual) in the menstrual cycle were investigated. Primary end-points were associations between changes in the core symptoms of premenstrual dysphoria, “irritable” and “depressed mood”, and changes in $^{11}$C-5-HTP trapping in a large brain region representing the “whole brain” and in specific areas of the forebrain that are known to be involved in affective disorders (Ågren and Reibring, 1994; Brody et al., 2001; Davidson, 2002).

2. Methods

2.1. Participants

Eight women were recruited for the study, one through our gynaecological admittance, and seven from subjects participating in a treatment trial published elsewhere (Landen et al., 2001). Inclusion criteria were: fulfillment of criteria A–C of PMDD as described in DSM-IV (American Psychiatric Association, 1994); fulfillment of criterion D by showing cyclicity of the core symptoms “irritability” and/or “depressed mood” in two of three visual analogue scale (VAS)-rated cycles. The inclusion criteria were thus a slightly modified version of the PMDD criteria of DSM-IV. The VAS instrument developed by Bäckström et al. and slightly modified from their first description (Hammarbäck et al., 1989). The assessed variables were irritability, depressed mood, fatigue, tension, happiness, energy, relaxation, friendliness, headache, bloating, breast tenderness, pelvic pain, craving for sweets and sexual desire. The subjects were instructed to mark total absence of a symptom as 0 mm on the VAS scale and the most intense form of the variable ever experienced by the individual as 100 mm.

2.2. Symptom evaluation

The subjects performed daily prospective self-ratings of four negative and four positive mood variables and six somatic symptoms associated with PMDD, using a VAS instrument developed by Bäckström et al. and slightly modified from their first description (Hammarbäck et al., 1989). The assessed variables were irritability, depressed mood, fatigue, tension, happiness, energy, relaxation, friendliness, headache, bloating, breast tenderness, pelvic pain, craving for sweets and sexual desire. The subjects were instructed to mark total absence of a symptom as 0 mm on the VAS scale and the most intense form of the variable ever experienced by the individual as 100 mm.

2.3. Imaging

PET scans were performed with a GEMS PC2048-15B scanner (General Electric Medical Systems, Milwaukee, WI, USA) with an axial field of view of 10 cm producing 15 slices spaced 6.5 mm apart with an in-
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات